{"id":"treatment-with-vismodegib","safety":{"commonSideEffects":[{"rate":"71","effect":"Muscle cramps"},{"rate":"63","effect":"Alopecia"},{"rate":"53","effect":"Dysgeusia (taste disturbance)"},{"rate":"45","effect":"Weight loss"},{"rate":"35","effect":"Fatigue"},{"rate":"30","effect":"Nausea"},{"rate":"28","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vismodegib is a small-molecule antagonist of Smoothened (SMO), a G-protein coupled receptor essential for Hedgehog pathway signaling. By blocking SMO, it prevents activation of downstream transcription factors (GLI1/GLI2) that drive proliferation in Hedgehog-dependent cancers. This mechanism is particularly effective in basal cell carcinoma, where aberrant Hedgehog signaling is a primary driver of tumorigenesis.","oneSentence":"Vismodegib inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:21.403Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced basal cell carcinoma"},{"name":"Metastatic basal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT01267955","phase":"PHASE2","title":"Vismodegib in Treating Patients With Advanced Chondrosarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-21","conditions":"Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma","enrollment":45},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT00878163","phase":"PHASE1","title":"GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03-31","conditions":"Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":55},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT02523014","phase":"PHASE2","title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-09-28","conditions":"Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation","enrollment":124},{"nctId":"NCT06616623","phase":"PHASE1","title":"Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2024-12-31","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":24},{"nctId":"NCT05651828","phase":"EARLY_PHASE1","title":"Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-03-23","conditions":"Advanced Basal Cell Carcinoma","enrollment":34},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT01878617","phase":"PHASE2","title":"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-23","conditions":"Medulloblastoma","enrollment":660},{"nctId":"NCT06357988","phase":"PHASE2","title":"Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-24","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT05561634","phase":"PHASE2","title":"Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-06-20","conditions":"Basal Cell Carcinoma, Radiotherapy; Complications","enrollment":82},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT01064622","phase":"PHASE2","title":"Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-03","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":118},{"nctId":"NCT06344052","phase":"PHASE2","title":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Stamford Pharmaceuticals, Inc.","startDate":"2024-04-09","conditions":"Basal Cell Carcinoma","enrollment":80},{"nctId":"NCT01774253","phase":"PHASE2","title":"Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma","status":"TERMINATED","sponsor":"Giselle Sholler","startDate":"2013-05","conditions":"Pontine Glioma","enrollment":9},{"nctId":"NCT02091141","phase":"PHASE2","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2014-04-14","conditions":"Neoplasms, Solid Tumors, Biliary Cancer","enrollment":673},{"nctId":"NCT05159245","phase":"PHASE2","title":"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2021-12-10","conditions":"Advanced Cancer, Solid Tumor, Haematological Malignancy","enrollment":250},{"nctId":"NCT04416516","phase":"PHASE2","title":"Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor","status":"COMPLETED","sponsor":"Ascend Biopharmaceuticals Ltd","startDate":"2020-07-16","conditions":"Basal Cell Carcinoma, Basal Cell Nevus Syndrome","enrollment":21},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04817956","phase":"PHASE2","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-01","conditions":"Cancer Metastatic","enrollment":3000},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT03158389","phase":"PHASE1, PHASE2","title":"NCT Neuro Master Match - N²M² (NOA-20)","status":"COMPLETED","sponsor":"University Hospital Heidelberg","startDate":"2018-05-07","conditions":"Glioblastoma, Adult","enrollment":228},{"nctId":"NCT02667574","phase":"PHASE2","title":"Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2014-11-18","conditions":"Basal Cell Carcinoma","enrollment":55},{"nctId":"NCT03610022","phase":"PHASE4","title":"Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2018-09-03","conditions":"Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma","enrollment":27},{"nctId":"NCT03035188","phase":"PHASE2","title":"Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma","status":"COMPLETED","sponsor":"SRH Wald-Klinikum Gera GmbH","startDate":"2017-01","conditions":"Basal Cell Carcinoma","enrollment":40},{"nctId":"NCT02337517","phase":"PHASE2","title":"Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Chronic Graft Versus Host Disease","enrollment":6},{"nctId":"NCT02366312","phase":"PHASE2","title":"A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors","status":"COMPLETED","sponsor":"NYU College of Dentistry","startDate":"2015-10-27","conditions":"Keratocystic Odontogenic Tumor","enrollment":2},{"nctId":"NCT00887159","phase":"PHASE2","title":"A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-16","conditions":"Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma","enrollment":168},{"nctId":"NCT01556009","phase":"PHASE2","title":"Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2012-04","conditions":"Basal Cell Nevus Syndrome, Gorlin's Syndrome","enrollment":24},{"nctId":"NCT02371967","phase":"","title":"A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-08","conditions":"Basal Cell Carcinoma","enrollment":50},{"nctId":"NCT02956889","phase":"PHASE2","title":"To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma","status":"TERMINATED","sponsor":"Istituto Clinico Humanitas","startDate":"2016-10","conditions":"Carcinoma, Basal Cell","enrollment":14},{"nctId":"NCT01601184","phase":"PHASE1, PHASE2","title":"Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway","status":"TERMINATED","sponsor":"Centre Leon Berard","startDate":"2012-06","conditions":"Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway","enrollment":24},{"nctId":"NCT01537107","phase":"PHASE1","title":"Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-03-05","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":31},{"nctId":"NCT02690948","phase":"PHASE1, PHASE2","title":"Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"Anne Chang","startDate":"2016-02-01","conditions":"Skin Basal Cell Carcinoma","enrollment":16},{"nctId":"NCT01163084","phase":"PHASE1, PHASE2","title":"Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-09","conditions":"Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7","enrollment":10},{"nctId":"NCT01108094","phase":"PHASE2","title":"Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-04","conditions":"Basal Cell Carcinoma (BCC), Skin Cancer","enrollment":29},{"nctId":"NCT01154452","phase":"PHASE1, PHASE2","title":"Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06","conditions":"Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor","enrollment":78},{"nctId":"NCT02115828","phase":"EARLY_PHASE1","title":"A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-04","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT02593760","phase":"PHASE1","title":"A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-01-25","conditions":"Myelofibrosis","enrollment":10},{"nctId":"NCT02438644","phase":"","title":"Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-30","conditions":"Basal Cell Carcinoma","enrollment":75},{"nctId":"NCT01631331","phase":"EARLY_PHASE1","title":"Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-06","conditions":"Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer","enrollment":15},{"nctId":"NCT02648048","phase":"PHASE1","title":"A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-01-15","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":21},{"nctId":"NCT02694224","phase":"PHASE2","title":"Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2016-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT01815840","phase":"PHASE2","title":"A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-04-30","conditions":"Basal Cell Carcinoma","enrollment":229},{"nctId":"NCT00980343","phase":"PHASE2","title":"GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":44},{"nctId":"NCT01195415","phase":"PHASE2","title":"Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06","conditions":"Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer","enrollment":25},{"nctId":"NCT01893892","phase":"NA","title":"Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-03","conditions":"Musculoskeletal Complications","enrollment":12},{"nctId":"NCT00968981","phase":"PHASE1","title":"A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-09","conditions":"Solid Cancers","enrollment":67},{"nctId":"NCT00739661","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-12","conditions":"Ovarian Cancer","enrollment":104},{"nctId":"NCT00636610","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-05","conditions":"Metastatic Colorectal Cancer","enrollment":199},{"nctId":"NCT01898598","phase":"PHASE2","title":"A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-23","conditions":"Basal Cell Carcinoma","enrollment":18},{"nctId":"NCT00939484","phase":"PHASE2","title":"Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-06","conditions":"Adult Medulloblastoma","enrollment":31},{"nctId":"NCT00982592","phase":"PHASE2","title":"Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer","enrollment":124},{"nctId":"NCT01239316","phase":"PHASE2","title":"Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Recurrent Childhood Medulloblastoma","enrollment":12},{"nctId":"NCT00607724","phase":"PHASE1","title":"GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-04","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":68},{"nctId":"NCT01209143","phase":"PHASE1","title":"A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Solid Cancers","enrollment":52},{"nctId":"NCT01071564","phase":"PHASE1","title":"RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative","enrollment":13},{"nctId":"NCT00959647","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-09","conditions":"Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer","enrollment":19},{"nctId":"NCT01330173","phase":"PHASE1","title":"Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":50},{"nctId":"NCT01201915","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-10","conditions":"Basal Cell Carcinoma","enrollment":74},{"nctId":"NCT00822458","phase":"PHASE1","title":"GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-01","conditions":"Recurrent Childhood Medulloblastoma","enrollment":34},{"nctId":"NCT01713218","phase":"EARLY_PHASE1","title":"Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer","status":"UNKNOWN","sponsor":"Jean-Luc Van Laethem","startDate":"2012-12","conditions":"Pancreatic Adenocarcinoma Resectable","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":915,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Treatment with vismodegib","genericName":"Treatment with vismodegib","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vismodegib inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation. Used for Locally advanced basal cell carcinoma, Metastatic basal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}